Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Indication: Zanubrutinib for Waldenstrom macroglobulinemia - Altai Oncology

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search

New Indication: Zanubrutinib for Waldenstrom macroglobulinemia

New Indication: Zanubrutinib for Waldenstrom macroglobulinemia
  • Randomized, open-label Phase III trial (ASPEN)
  • WM pts requiring treatment at any line
  • Cohort 1: MYD88 L265P mutated pts => zanubrutinib 160 mg BID (n=102) vs. ibrutinib 420 mg daily (n=99)
  • Cohort 2: MYD88 WT or unknown => all received zanubrutinib (n=28)
  • Cohort 1 => Major response: 77% vs. 78%; VGPR: 31% vs. 20%, PFS @ 18 mos: 85% vs. 84%
  • Cohort 2 => Major response: 50%
  • Grade >= 3 AEs: Neutropenia (20% vs. 8%), thrombocytopenia (6% vs. 3%), hypertension (6% vs. 11%), atrial fibrillation (none vs. 4%), pneumonia (1% vs. 7%), hematuria (none vs. 2%)

Blood (2020) 136 (18): 2038–2050

Tam CS, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study


Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More